Plain-English translation of NCT06073938 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study of , a new cancer medication being tested in patients with advanced solid tumors or lymphomas that carry a genetic change called NUT rearrangement. The study will look at how well the medication works and how safe it is. Researchers also want to identify which patients are most likely to benefit from this treatment to help design future trials.
NUT rearrangement cancers are rare and aggressive, and current treatment options are limited. This medication may offer a new hope for patients with these specific cancers by targeting the underlying genetic change.
You likely qualify if…
You likely don't qualify if…
In this study, you would take the medication as part of your cancer treatment. The research team will monitor how well the medication works against your cancer and track any side effects you experience. You'll likely have regular medical visits, blood tests, and imaging scans to assess your response to treatment and gather information about biomarkers that might predict who benefits most from this medication.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China
Sponsor
Hunan Province Tumor Hospital
Enrollment target
~30 participants
Started
September 2022
Primary completion
December 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yongchang Zhang, MD
Hunan Province Tumor Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.